102 research outputs found

    Economics of dialysis dependence following renal replacement therapy for critically ill acute kidney injury patients.

    Get PDF
    BACKGROUND: The obective of this study was to perform a cost-effectiveness analysis comparing intermittent with continuous renal replacement therapy (IRRT versus CRRT) as initial therapy for acute kidney injury (AKI) in the intensive care unit (ICU). METHODS: Assuming some patients would potentially be eligible for either modality, we modeled life year gained, the quality-adjusted life years (QALYs) and healthcare costs for a cohort of 1000 IRRT patients and a cohort of 1000 CRRT patients. We used a 1-year, 5-year and a lifetime horizon. A Markov model with two health states for AKI survivors was designed: dialysis dependence and dialysis independence. We applied Weibull regression from published estimates to fit survival curves for CRRT and IRRT patients and to fit the proportion of dialysis dependence among CRRT and IRRT survivors. We then applied a risk ratio reported in a large retrospective cohort study to the fitted CRRT estimates in order to determine the proportion of dialysis dependence for IRRT survivors. We conducted sensitivity analyses based on a range of differences for daily implementation cost between CRRT and IRRT (base case: CRRT day 632moreexpensivethanIRRTday;rangefrom632 more expensive than IRRT day; range from 200 to 1000)andarangeofriskratiosfordialysisdependenceforCRRTascomparedwithIRRT(from0.65to0.95;basecase:0.80).RESULTS:ContinuousrenalreplacementtherapywasassociatedwithamarginallygreatergaininQALYascomparedwithIRRT(1.093versus1.078).DespitehigherupfrontcostsforCRRTintheICU(1000) and a range of risk ratios for dialysis dependence for CRRT as compared with IRRT (from 0.65 to 0.95; base case: 0.80). RESULTS: Continuous renal replacement therapy was associated with a marginally greater gain in QALY as compared with IRRT (1.093 versus 1.078). Despite higher upfront costs for CRRT in the ICU (4046 for CRRT versus 1423forIRRTinaverage),the5yeartotalcostincludingthecostofdialysisdependencewaslowerforCRRT(1423 for IRRT in average), the 5-year total cost including the cost of dialysis dependence was lower for CRRT (37 780 for CRRT versus $39 448 for IRRT on average). The base case incremental cost-effectiveness analysis showed that CRRT dominated IRRT. This dominance was confirmed by extensive sensitivity analysis. CONCLUSIONS: Initial CRRT is cost-effective compared with initial IRRT by reducing the rate of long-term dialysis dependence among critically ill AKI survivors

    The authors reply.

    No full text

    Controversies in acute kidney injury

    No full text
    Acute kidney injury (AKI) is a serious and as yet incompletely understood disorder in which sudden impairment of kidney function occurs secondary to one or more of a variety of underlying conditions. This disorder is very common in (elderly) ICU patients and is associated with very high mortality. Many of those who survive suffer from permanent kidney failure and other long-term morbidities, which may include cardiovascular disease and immune dysfunction. Epidemiologic evidence suggests that AKI is not a single disease, but a syndrome comprised of multiple, often coexisting, etiologies. Being usually part of multiorgan failure syndrome, it calls for multiple organ support therapy. The publication at hand contains sections on prerenal azotemia syndromes, dying 'of' or 'with' AKI, pathophysiology of sepsis-induced acute kidney injury, developments in prevention/treatment/rehabilitation, and renal support. Reporting the latest recommendations from experts, it provides valuable information for those that are interested in understanding the disorder and its treatment options.SCOPUS: bk.binfo:eu-repo/semantics/publishe

    Unveiling current controversies in acute kidney injury

    Get PDF
    SCOPUS: ch.binfo:eu-repo/semantics/publishe

    Bench to bedside review: Extracorporeal carbon dioxide removal, past present and future

    No full text
    10.1186/cc11356Critical Care16523
    corecore